Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

640
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
640
Destabilization of Microtubules01:45

Destabilization of Microtubules

3.1K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.3K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

901
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
901
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

102
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
102

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Structure-aware fatigue modeling in foot deformities: A digital health framework for tissue-specific running injury risk prediction using multi-modal data.

PLOS digital health·2026
Same author

Spatiotemporal inequities in early-life ecological liveability and sleep health in preschool children.

Environmental pollution (Barking, Essex : 1987)·2026
Same author

Understanding the "how" and "why": A mixed methods process evaluation for the PRO-HIIT intervention.

PloS one·2026
Same author

Interlimb differences in knee joint loading and stress distribution following anterior cruciate ligament reconstruction during stair descent.

Clinical biomechanics (Bristol, Avon)·2026
Same author

CAFE: Cross-View Adaptive Fusion and Cluster Center Enhancement for Robust Multi-View Clustering.

IEEE transactions on pattern analysis and machine intelligence·2026
Same author

Cross-Category Screening of Food Samples for Amyloid-β42 Aggregation-Inhibitory Activity Using a Microliter-Scale High-Throughput Screening System with Quantum-Dot-Labeled Aβ.

Foods (Basel, Switzerland)·2026

関連する実験動画

Updated: Nov 4, 2025

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.4K

MARK4は,マイクロチューブルのオキシトシネーションによって,心不全を制御する.

Xian Yu1, Xiao Chen2, Mamta Amrute-Nayak3

  • 1Department of Medicine, Cardiovascular Division, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

Nature
|May 27, 2021
PubMed
まとめ

微小管親和調節キナーゼ4 (MARK4) 欠乏症は,マウスにおける心筋梗塞後の心臓機能を改善する. MARK4は微小管による心筋細胞の収縮性を調節し,心不全の治療対象となる可能性がある.

さらに関連する動画

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.9K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.1K

関連する実験動画

Last Updated: Nov 4, 2025

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae
07:51

Mechanical Control of Relaxation Using Intact Cardiac Trabeculae

Published on: February 17, 2023

1.4K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.9K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.1K

科学分野:

  • 心臓病科
  • 分子生物学
  • 細胞生物学

背景:

  • 心筋梗塞 (MI) は主要な死因であり,しばしば心不全につながる.
  • 心不全に対する現在のイノトロピック療法には重大なリスクと限られた有効性があります.
  • 微小管のオキシトシネーションは,心臓肌細胞の収縮性の新発見のレギュラーである.

研究 の 目的:

  • 心筋梗塞後の心機能における微小管親和調節キナーゼ4 (MARK4) の役割を調査する.
  • 心筋細胞の収縮性と微小管のオキシトシン化を調節するMARK4のメカニズムを探求する.

主な方法:

  • 急性心筋梗塞のマウスモデルを使用した.
  • 心臓機能の評価 左心室のエジェクション分数,心臓発作の大きさ,心臓の改造
  • 心筋細胞におけるMARK4,MAP4,VASH2,α-チューブリンオキソシネーションを含む分子メカニズムを調査した.

主要な成果:

  • マウスにおけるMARK4欠乏症は,心筋梗塞の後に左心室のエジェクション分子を有意に保存した.
  • MARK4欠乏症は心臓発作の大きさや心臓の改造を変化させなかった.
  • MARK4は,MAP4をリン酸化し,VASH2媒介の微小管結合を強めることで,心筋細胞の収縮性を促進する.

結論:

  • MARK4は,微小管のオキシトシネーションによって心臓のイノトロピーを調節する上で重要な役割を果たします.
  • 心筋梗塞後の心臓機能を改善するための有望な治療戦略です.